Immuneering (NASDAQ:IMRX) Stock Price Down 0.9% – Here’s What Happened

Immuneering Corporation (NASDAQ:IMRX)’s share price was down 0.9% on Thursday . The stock traded as low as $4.47 and last traded at $4.57. 623,957 shares traded hands during mid-day trading, an increase of 0% from the average daily volume of 621,096 shares. The stock had previously closed at $4.61.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on IMRX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Wednesday, June 24th. UBS Group set a $14.00 target price on Immuneering in a report on Thursday, August 6th. HC Wainwright reaffirmed a “buy” rating on shares of Immuneering in a research report on Thursday, August 27th. Wall Street Zen lowered shares of Immuneering from a “hold” rating to a “sell” rating in a research note on Monday, July 20th. Finally, Cantor Fitzgerald assumed coverage on shares of Immuneering in a research report on Wednesday, July 8th. They set an “overweight” rating and a $17.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Immuneering has a consensus rating of “Buy” and an average target price of $17.50.

Immuneering Price Performance

The stock has a market cap of $295.68 million, a price-to-earnings ratio of -4.39 and a beta of 0.40. The business’s 50 day moving average is $4.83 and its 200 day moving average is $4.99.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.01). As a group, analysts forecast that Immuneering Corporation will post -1.09 earnings per share for the current year.

Hedge Funds Weigh In On Immuneering

A number of institutional investors and hedge funds have recently added to or reduced their stakes in IMRX. Caitong International Asset Management Co. Ltd purchased a new position in Immuneering in the fourth quarter valued at approximately $33,000. Integrated Wealth Concepts LLC purchased a new position in shares of Immuneering in the 2nd quarter valued at $34,000. Levin Capital Strategies L.P. purchased a new position in shares of Immuneering in the 1st quarter valued at $53,000. Mercer Global Advisors Inc. ADV acquired a new stake in Immuneering during the 3rd quarter worth $70,000. Finally, SummitTX Capital L.P. acquired a new stake in Immuneering during the 4th quarter worth $69,000. 67.65% of the stock is owned by institutional investors and hedge funds.

About Immuneering

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.